SMARCB1 and synovial sarcoma: On these grounds, BRD9 targeting using PROTAC degraders is currently under investigation in a phase 1 clinical trial (NCT04965753) in patients with advanced synovial sarcoma or advanced SMARCB1-loss tumors.